| ||
| Developer of New Treatment for Severe Asthma Episodes Expects Phase 2 Clinical ... MarketWatch (press release) ... the Founder, President and Chief Executive Officer of MediciNova, Inc. (NASDAQ:MNOV) tells investors about a promising treatment approach aimed at meeting the need for novel treatments for patients suffering from acute exacerbations of asthma (AEA) ... See all stories on this topic » | ||
| Emergency Department Visits for Asthma in Children Medscape The current recommendations regarding initiation of controller medications in children seen in the emergency department (ED) for exacerbation of asthma are confusing. For example, in the United States, the National Heart, Lung, and Blood Institute's ... See all stories on this topic » | ||
| ||
| ||
| Novartis announces Aliskiren will continue to be available to appropriate ... Reuters Aliskiren-based products will continue to be available in the US for the treatment of high blood pressure in appropriate patients. Furthermore, and in consultation with the FDA, Novartis has decided to voluntarily cease marketing in the US of Valturna ... See all stories on this topic » |
| ||
| Feasibility of Percutaneous Vagus Nerve ... - Wiley Online Library Objectives: This study assessed the feasibility of an investigational vagus nerve stimulation (VNS) device for treating acute asthma exacerbations in patients not ... onlinelibrary.wiley.com/doi/10.1111/j.1553-2712...x/full |
Tip: Use site restrict in your query to search within a site (site:nytimes.com or site:.edu). Learn more.
Delete this alert.
Create another alert.
Manage your alerts.
No comments:
Post a Comment